On March 12, 2026 Mestag Therapeutics ("Mestag"), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, reported that it will be presenting a poster at the Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations Keystone Symposia taking place March 15-18, 2026, in Québec City, Canada, titled "MST-0312: FAP-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Details:
Title: MST-0312: FAP-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors
Poster Number: 1037
Date: March 16, 2026
Time: 1:00-3:00 p.m. ET
Session Title: Poster Session 1
About MST-0312
MST-0312 is a first-in-class targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) in solid tumors. A remarkable body of clinical evidence correlates the presence of TLS and HEV in tumors with improved response to treatment and patient survival outcomes. It is believed that TLS/HEV formation drives improved access of lymphocytes into tumor tissue, and facilitates local education and activation to tumor antigens. LTBR is the key pathway driving TLS/HEV formation. Preclinical studies show that MST-0312 monotherapy induces strong, dose-dependent anti-tumor responses, including in low-antigen tumors that are typically resistant to immunotherapy. MST-0312 is planned to enter the clinic in 2026 with the initiation of the Phase 1 STARLYS trial, advised by leading cancer experts.
(Press release, Mestag Therapeutics, MAR 12, 2026, View Source [SID1234663525])